Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_provenance.
- NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_provenance.
- NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_assertion evidence source_evidence_literature NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_provenance.
- NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_assertion SIO_000772 20080466 NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_provenance.
- NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_assertion wasDerivedFrom befree-20150227 NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_provenance.
- NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_assertion wasGeneratedBy ECO_0000203 NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_provenance.
- befree-20150227 importedOn "2015-02-27" NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_provenance.